Edwards Lifesciences Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Edwards Lifesciences Corp Unternehmen

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corp Informationen



BörsenkürzelEW

Name des UnternehmensEdwards Lifesciences Corp

IPO-datumMar 27, 2000

CEOZovighian (Bernard J)

Anzahl der mitarbeiter15800

WertpapierartOrdinary Share

GeschäftsjahresendeMar 27

AddresseOne Edwards Way

StadtIRVINE

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl92614

Telefon19492502500

Websitehttps://www.edwards.com

BörsenkürzelEW

IPO-datumMar 27, 2000

CEOZovighian (Bernard J)

Führungskräfte von Edwards Lifesciences Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+4682.00%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

--

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

17.91K

-2000.00%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+3528.00%

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Ms. Leslie S. Heisz

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+4682.00%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

--

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

17.91K

-2000.00%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+3528.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Transcatheter Aortic Valve Replacement

1.15B

74.04%

Surgical Heart Valve Therapy

258.00M

16.61%

Transcatheter Mitral and Tricuspid Therapies

145.20M

9.35%

Nach RegionUSD

Name

Umsatz

Anteil

United States

907.50M

58.43%

Europe

387.90M

24.98%

Rest of the world

167.60M

10.79%

Japan

90.10M

5.80%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Transcatheter Aortic Valve Replacement

1.15B

74.04%

Surgical Heart Valve Therapy

258.00M

16.61%

Transcatheter Mitral and Tricuspid Therapies

145.20M

9.35%

Aktionärsstatistik

Aktualisiert: Sat, Jan 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

12.03%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

Andere

71.62%

Aktionäre

Anteil

The Vanguard Group, Inc.

12.03%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

Andere

71.62%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

46.83%

Investment Advisor/Hedge Fund

30.96%

Hedge Fund

3.47%

Pension Fund

2.27%

Research Firm

2.17%

Bank and Trust

1.96%

Sovereign Wealth Fund

1.37%

Individual Investor

0.93%

Endowment Fund

0.83%

Andere

9.21%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

2452

517.66M

93.53%

--

2025Q3

2537

517.80M

94.00%

-1.50M

2025Q2

2614

519.17M

94.35%

-5.19M

2025Q1

2599

525.51M

93.66%

-25.15M

2024Q4

2585

522.16M

89.45%

+17.15M

2024Q3

2546

504.88M

87.53%

-10.03M

2024Q2

2541

515.71M

87.77%

+1.93M

2024Q1

2555

513.21M

86.74%

-8.92M

2023Q4

2556

503.19M

87.55%

-12.35M

2023Q3

2509

516.79M

88.03%

-521.37K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

70.09M

12.08%

+359.01K

+0.51%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

30.52M

5.26%

-370.16K

-1.20%

Sep 30, 2025

State Street Investment Management (US)

25.62M

4.41%

-14.75K

-0.06%

Sep 30, 2025

Wellington Management Company, LLP

20.80M

3.59%

+977.93K

+4.93%

Sep 30, 2025

JP Morgan Asset Management

17.92M

3.09%

-2.17M

-10.80%

Sep 30, 2025

Jennison Associates LLC

13.96M

2.41%

+2.29M

+19.60%

Sep 30, 2025

Fidelity Management & Research Company LLC

13.03M

2.25%

+10.73M

+466.56%

Sep 30, 2025

Geode Capital Management, L.L.C.

12.84M

2.21%

+114.73K

+0.90%

Sep 30, 2025

Walter Scott & Partners Ltd.

9.96M

1.72%

+1.05M

+11.73%

Sep 30, 2025

Union Investment Privatfonds GmbH

8.60M

1.48%

+19.17K

+0.22%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares U.S. Medical Devices ETF

4.72%

Future Fund Long/Short ETF

3.86%

iShares Health Innovation Active ETF

3.65%

Global X Aging Population ETF

3.31%

Acruence Active Hedge US Equity ETF

2.58%

First Trust Indxx Medical Devices ETF

2.23%

State Street SPDR S&P Health Care Equipment ETF

1.88%

JPMorgan Healthcare Leaders ETF

1.8%

PGIM Jennison Better Future ETF

1.78%

ROBO Global Healthcare Technology & Innovation ETF

1.73%

iShares U.S. Medical Devices ETF

Anteil4.72%

Future Fund Long/Short ETF

Anteil3.86%

iShares Health Innovation Active ETF

Anteil3.65%

Global X Aging Population ETF

Anteil3.31%

Acruence Active Hedge US Equity ETF

Anteil2.58%

First Trust Indxx Medical Devices ETF

Anteil2.23%

State Street SPDR S&P Health Care Equipment ETF

Anteil1.88%

JPMorgan Healthcare Leaders ETF

Anteil1.8%

PGIM Jennison Better Future ETF

Anteil1.78%

ROBO Global Healthcare Technology & Innovation ETF

Anteil1.73%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

May 07, 2020

Split

1→3

Datum

Ex-Dividendentag

Art

Verhältnis

May 07, 2020

Split

1→3